Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Broad Licenses Gene-Editing Technology

by Ann M. Thayer
December 8, 2014 | A version of this story appeared in Volume 92, Issue 49

Editas Medicine has set up an exclusive licensing agreement around genome-editing technology with Harvard University and the Broad Institute of MIT & Harvard. Editas intends to use targeted gene-modification techniques to find disease therapies. It will focus on clustered, regularly interspaced, short, palindromic repeats (CRISPR) and CRISPR-associated protein 9 (Cas9), along with transcription-activator-like effector nucleases, or TALENs, to directly turn on, turn off, or edit disease-causing genes. Separately, the Broad Institute has licensed the CRISPR/Cas9 technology to Sigma-Aldrich, which will make, use, and sell gene-editing tools for research applications.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.